ARTMS and Telix Pharmaceuticals Announce Manufacturing Collaboration
VANCOUVER (British Columbia) and MELBOURNE (Australia) 6th May 2020 – ARTMS Products Inc. and Telix Pharmaceuticals Limited have entered into a development collaboration agreement
Telix is pleased to announce it has entered into a development collaboration agreement with ARTMS Products Inc. (ARTMS), a global leader in the development of novel technologies enabling the production of the world’s highest demand diagnostic imaging isotopes, to employ ARTMS’ high activity production of Gallium-68 (68Ga) for the manufacture of Telix’s prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11 injection) for the imaging of prostate cancer with Positron Emission Tomography (PET).
To read the full press release please click here.
The Role of Patents in Drug Development – Telix in Australian Biotechnology Journal
5 October 2022 | Corporate Spotlight | Telix in Australasian Biotechnology Journal – The Role of Patents in Drug Development
First Patient in New Zealand Dosed with Illuccix® – Telix’s Prostate Cancer Imaging Agent
Melbourne – 30 September 2022. First Patient in New Zealand Dosed with Illuccix® – Telix’s Prostate Cancer Imaging Agent
Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
Melbourne – 28 September 2022. Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate